Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHRONO-RCC: Timing of Nivolumab/Ipilimumab in Advanced Kidney Cancer
NCT07338981Phase 3Not yet recruiting
- Start
- Feb 2027
- Primary completion
- Dec 2031
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of nivolumab and ipilimumab in Clear Cell Renal Cell Carcinoma (ccRCC) (2 arms). Primary endpoint: Overall Survival at 24 months. Planned start Feb 2027; status: not yet recruiting.
02
Drugs
nivolumabipilimumab
03
Conditions
Clear Cell Renal Cell Carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT07338981.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07338981.